companies / eg427-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-02 json
| total_raised | 43,200,00043.2M | ○ |
|---|---|---|
| founded | 2021 | |
| hq | Paris, France | |
| industry | unknown | |
| stage | series-b+ |
EG 427 is a Paris-based biotech developing DNA medicines on a non-replicative Herpes Simplex Virus 1 platform that delivers durable gene expression to peripheral neurons. It focuses on patients with severe localized chronic diseases of the peripheral nervous system, starting with bladder disorders. HSV-1 latency lets it deliver large payloads.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2025-02-15 | series-b | 29,160,00029.2M | null | ○ |
Cloudflare, PHP, YouTube, Unpkg, jsDelivr, Plesk, core-js, Alpine.js
| fact | status | src |
|---|---|---|
| Series B, $29.2M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |